Fampridine Accord: Uses, Dosage & Side Effects

What Is Fampridine Accord and What Is It Used For?

Fampridine Accord contains the active substance fampridine, a small molecule also known chemically as 4-aminopyridine (4-AP). In the United States, the same active substance is marketed under the name dalfampridine. Fampridine Accord is a generic version of the originator product Fampyra (marketed in Europe) and Ampyra (marketed in the United States), both of which contain identical 10 mg prolonged-release fampridine tablets. The prolonged-release formulation is critically important because it provides a slow, controlled release of the active substance over several hours, resulting in lower peak plasma concentrations compared to immediate-release preparations. This controlled-release profile is essential for reducing the risk of dose-related seizures, which is the most significant safety concern associated with fampridine.

Fampridine Accord is indicated for the improvement of walking in adult patients with multiple sclerosis who have walking disability. This corresponds to an Expanded Disability Status Scale (EDSS) score of 4 to 7, which encompasses patients ranging from those who can walk limited distances without aid to those who require bilateral assistance. Multiple sclerosis is a chronic autoimmune disease of the central nervous system in which the immune system attacks and destroys myelin, the protective sheath surrounding nerve fibers (axons) in the brain and spinal cord. This process, known as demyelination, disrupts the transmission of electrical signals along nerve pathways. When nerve fibers that control leg movement and coordination are affected, patients experience progressive walking difficulty, reduced walking speed, increased fatigue during walking, and impaired balance and coordination.

The mechanism of action of fampridine directly addresses the consequences of demyelination at the molecular level. In healthy nerve fibers, voltage-gated potassium channels are located beneath the myelin sheath, where they play a role in repolarizing the nerve membrane after an action potential has passed. These channels are normally inaccessible because the myelin insulation prevents potassium ions from leaking out during signal propagation. However, when myelin is lost through the demyelination process in MS, these potassium channels become exposed to the extracellular space. The resulting potassium ion leakage during action potential propagation shortens the action potential duration, reduces its amplitude, and can completely block nerve signal transmission at the site of demyelination. This is one of the key mechanisms underlying neurological disability in MS.

By blocking these exposed voltage-gated potassium channels, fampridine reduces the leakage of potassium ions from the nerve fiber. This prolongs the duration and increases the amplitude of action potentials in demyelinated axons, allowing nerve impulses to cross areas of demyelination more effectively. The result is improved nerve conduction velocity and more reliable signal transmission from the brain and spinal cord to the muscles involved in walking. This translates clinically into faster walking speed, improved walking endurance, increased step length, and enhanced overall mobility for patients who respond to the treatment.

The efficacy of fampridine for improving walking in MS was established in two pivotal phase III, randomized, double-blind, placebo-controlled clinical trials (MS-F203 and MS-F204). In these studies, approximately 35–43% of patients treated with fampridine 10 mg twice daily were classified as “timed walk responders,” meaning they showed a consistently faster walking speed during the treatment period compared to non-treatment visits, as measured by the Timed 25-Foot Walk (T25FW) test. By contrast, only 8–9% of placebo-treated patients met this responder criterion. Responders experienced an average improvement in walking speed of approximately 25%, which was clinically meaningful and perceptible to both patients and clinicians. The improvement was also reflected in better scores on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), a patient-reported outcome measure that captures subjective walking ability.

What Should You Know Before Taking Fampridine Accord?

Contraindications

Fampridine Accord is contraindicated (must not be used) in several specific clinical situations that significantly increase the risk of serious adverse events. The most critical contraindication is a history of seizures (epilepsy). Fampridine lowers the seizure threshold in a dose-dependent manner, and patients with a history of seizures are at substantially increased risk of experiencing convulsions during treatment, even at the recommended therapeutic dose of 10 mg twice daily. Clinical trials excluded patients with any seizure history, and post-marketing surveillance has confirmed that seizures occur more frequently in patients who have predisposing risk factors.

The second major contraindication involves renal function. Fampridine is contraindicated in patients with moderate or severe renal impairment, defined as a creatinine clearance of less than 80 mL/min. Because approximately 90% of fampridine is eliminated unchanged through the kidneys, impaired renal function leads to significantly higher and more prolonged plasma concentrations of the drug. This accumulation increases the risk of concentration-dependent adverse effects, particularly seizures. Mild renal impairment (creatinine clearance of 51–80 mL/min) requires caution, and dose adjustment may be considered, but moderate and severe impairment are absolute contraindications. Renal function should be assessed before starting treatment and monitored periodically during therapy, particularly in elderly patients whose renal function may decline over time.

Additionally, Fampridine Accord must not be used concurrently with any other fampridine-containing product (including compounded 4-aminopyridine preparations). Concomitant use would effectively increase the dose beyond the safe therapeutic range, dramatically increasing seizure risk. Hypersensitivity to fampridine or any of the excipient components of the tablet is also a contraindication.

Warnings and Precautions

Before and during treatment with Fampridine Accord, several precautions should be carefully considered and discussed with your healthcare provider:

• Seizure risk: Even in patients without a seizure history, fampridine can trigger seizures. The risk is dose-dependent and increases with higher plasma concentrations. Strict adherence to the recommended dosing schedule (one 10 mg tablet every 12 hours) is essential. Patients should be informed about the signs and symptoms of seizures and instructed to discontinue treatment immediately and seek medical attention if a seizure occurs.
• Renal function monitoring: Because fampridine is predominantly eliminated by the kidneys, creatinine clearance should be measured before starting treatment and at regular intervals thereafter (at least annually, or more frequently in patients at risk of declining renal function). Any significant decline in renal function during treatment should prompt reassessment of whether continued use is appropriate.
• Cardiac arrhythmias: Fampridine blocks potassium channels, which are also present in cardiac tissue. While clinical trials did not identify significant cardiac safety signals at the recommended dose, caution is advised in patients with a history of cardiac arrhythmias or QT prolongation. ECG monitoring may be considered in patients with pre-existing cardiac conduction abnormalities.
• Infections: Urinary tract infections have been reported more frequently in patients taking fampridine compared to placebo. Patients should be counseled about the symptoms of urinary tract infection and encouraged to seek prompt medical attention if these occur.
• Allergic reactions: Serious allergic reactions including anaphylaxis have been reported in post-marketing surveillance. Patients who develop signs of anaphylaxis (difficulty breathing, swelling of the face or throat, skin rash, rapid heartbeat) should discontinue the medication immediately and seek emergency medical care.

Pregnancy and Breastfeeding

There are limited data on the use of fampridine in pregnant women. Animal studies have shown reproductive toxicity at doses significantly higher than the therapeutic dose, including reduced fetal weight and increased skeletal variations. As a precaution, Fampridine Accord should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the fetus. Women of childbearing potential should be advised to use effective contraception during treatment.

It is not known whether fampridine or its metabolites are excreted in human breast milk. Animal studies have shown that fampridine is excreted in milk. Given the potential for serious adverse effects in breastfed infants, particularly the risk of seizures, a decision should be made whether to discontinue breastfeeding or to discontinue Fampridine Accord treatment, taking into account the importance of the medication to the mother. The long elimination half-life of approximately 6 hours should be considered when planning the timing of breastfeeding in relation to dosing.

Elderly Patients

Clinical trials of fampridine did not include sufficient numbers of patients aged 65 and older to determine whether they respond differently from younger patients. Elderly patients are more likely to have decreased renal function, which increases the risk of higher fampridine plasma concentrations and associated adverse effects, including seizures. Renal function must be assessed before starting treatment in elderly patients, and more frequent monitoring is recommended. Dose adjustment based on renal function should be considered, and the medication should not be initiated if creatinine clearance is below 80 mL/min.

Driving and Operating Machinery

Fampridine may cause dizziness, a commonly reported side effect. Patients who experience dizziness should be advised not to drive or operate machinery until the symptom resolves. Additionally, because seizures are a known risk of treatment, patients should be informed about the potential impact of a seizure on their ability to safely drive or operate heavy equipment. Healthcare providers should counsel patients about these risks at the time of prescription.

How Does Fampridine Accord Interact with Other Drugs?

Fampridine has a relatively narrow therapeutic index, meaning the difference between therapeutic and toxic plasma concentrations is small. Understanding its drug interactions is therefore particularly important for safe use. Unlike many medications, fampridine is not significantly metabolized by cytochrome P450 (CYP) enzymes in the liver. Instead, approximately 90% of the administered dose is eliminated unchanged through the kidneys, primarily via active tubular secretion mediated by organic cation transporter 2 (OCT2). This renal elimination pathway is the primary route for clinically significant drug interactions.

Fampridine itself is also a substrate and inhibitor of OCT2, which means it can both be affected by and affect other drugs that use this transporter. The most significant drug interactions are outlined in the table below:

Major Interactions

The most clinically significant interaction is with OCT2 inhibitors, of which cimetidine is the best-characterized example. In a pharmacokinetic study, co-administration of cimetidine with fampridine resulted in an approximately 22% increase in fampridine plasma levels. Because fampridine has a narrow therapeutic window and seizure risk increases with plasma concentration, this elevation is clinically meaningful. Concomitant use of fampridine with potent OCT2 inhibitors is therefore not recommended. If an OCT2 inhibitor must be used, careful monitoring for signs of fampridine toxicity (including tremor, dizziness, paresthesia, and particularly seizure activity) is essential.

The combination with other fampridine-containing products is absolutely contraindicated. Some patients may have previously used compounded (non-commercial) 4-aminopyridine preparations, which are sometimes available from compounding pharmacies. These must be completely discontinued before starting Fampridine Accord, and patients must be explicitly counseled never to use both products simultaneously, as the combined dose would exceed the safe therapeutic range.

Minor Interactions

Fampridine has been studied extensively in combination with disease-modifying therapies commonly used in MS, including interferon beta-1a, interferon beta-1b, glatiramer acetate, natalizumab, fingolimod, and dimethyl fumarate. No clinically significant pharmacokinetic or pharmacodynamic interactions have been identified with any of these agents. This is important because most MS patients receiving fampridine will also be on concurrent disease-modifying therapy. Similarly, no significant interactions have been identified with commonly used symptomatic medications in MS, including antispasticity agents (baclofen, tizanidine), antidepressants, and pain medications, although caution is always warranted with drugs that lower the seizure threshold.

What Is the Correct Dosage of Fampridine Accord?

Adults

The recommended dose of Fampridine Accord for adult patients is one 10 mg prolonged-release tablet taken twice daily, with an interval of approximately 12 hours between doses (for example, one tablet in the morning and one tablet in the evening). The total daily dose is 20 mg. This dosing regimen was established through extensive dose-finding studies and represents the optimal balance between efficacy and safety. Higher doses were associated with a significantly increased risk of seizures without a proportionate increase in walking improvement.

The tablets must be taken without food or with a light meal. While food does not significantly affect the total amount of fampridine absorbed, high-fat meals can increase the peak plasma concentration (Cmax) and reduce the time to peak concentration (Tmax). Taking the medication in a fasted state or with a light meal helps maintain the consistent pharmacokinetic profile that the prolonged-release formulation is designed to achieve.

Critically, the prolonged-release tablets must be swallowed whole with a glass of water. They must not be divided, crushed, dissolved, sucked, or chewed. Breaking the tablet destroys the prolonged-release mechanism and results in an immediate release of the entire 10 mg dose, producing a rapid spike in plasma concentration that significantly increases the risk of seizures and other concentration-dependent adverse effects.

Children and Adolescents

Fampridine Accord is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of fampridine have not been established in pediatric patients. Multiple sclerosis in children and adolescents is a distinct clinical entity that requires specialized treatment approaches, and fampridine has not been studied in this population. Healthcare providers managing pediatric MS patients should consider age-appropriate alternatives for managing walking difficulty and other symptoms.

Missed Dose

If you forget to take a dose of Fampridine Accord, do not take a double dose to make up for the missed one. Simply skip the missed dose and take the next dose at the regular scheduled time, maintaining the approximately 12-hour interval between doses. Taking two tablets at once or within a short time interval significantly increases the peak plasma concentration and the risk of seizures. It is helpful to set reminders or use a pill organizer to maintain a consistent dosing schedule.

Overdose

Overdose of fampridine is a medical emergency due to the dose-dependent risk of seizures. Symptoms of overdose may include confusion, tremor, diaphoresis (excessive sweating), amnesia, seizures (including status epilepticus), and cardiac arrhythmias. There is no specific antidote for fampridine overdose. Treatment is supportive and symptomatic, with particular attention to seizure management using standard anticonvulsant protocols (typically benzodiazepines as first-line therapy). Because fampridine is primarily eliminated by the kidneys, adequate hydration and maintenance of renal function are important in the management of overdose. In cases of severe overdose, hemodialysis may be considered, although its effectiveness has not been specifically studied.

If you suspect an overdose, contact your local poison control center or emergency services immediately, even if no symptoms are present, as seizures may occur with a delayed onset.

What Are the Side Effects of Fampridine Accord?

Like all medicines, Fampridine Accord can cause side effects, although not everybody gets them. The overall safety profile has been characterized through clinical trials involving more than 600 MS patients treated with fampridine 10 mg twice daily, as well as extensive post-marketing surveillance data. In clinical trials, approximately 8.6% of patients discontinued treatment due to adverse events, compared with 5.3% of placebo-treated patients. The most common reasons for discontinuation were insomnia, dizziness, and balance disorder.

Side effects are classified below by frequency according to the standard Medical Dictionary for Regulatory Activities (MedDRA) convention:

Urinary tract infections were the most frequently reported adverse event in clinical trials, occurring in approximately 12% of fampridine-treated patients compared with 8% of placebo-treated patients. This slightly higher incidence is thought to be related to the pharmacological effects of fampridine on bladder function rather than a direct immunosuppressive effect. Patients should be counseled about the symptoms of urinary tract infection (painful urination, increased frequency, urgency, cloudy or strong-smelling urine) and encouraged to seek prompt medical attention if these occur.

Neurological side effects such as dizziness, balance disorder, paraesthesia, and tremor are consistent with the pharmacological mechanism of action of fampridine, which affects potassium channel activity in the nervous system. These effects are generally dose-related and tend to be mild to moderate in severity. They often occur early in treatment and may diminish with continued use as the body adjusts to the medication. However, if these symptoms are severe or persistent, they may warrant dose reassessment or treatment discontinuation.

Seizures, while classified as uncommon, represent the most serious adverse effect of fampridine. In clinical trials, the incidence of seizures was approximately 0.4% in patients receiving the recommended dose of 10 mg twice daily. Seizures are dose-dependent and are more likely to occur with higher plasma concentrations, which can result from overdose, impaired renal function, or drug interactions that reduce fampridine clearance. If a seizure occurs, treatment must be discontinued immediately and permanently.

How Should You Store Fampridine Accord?

Proper storage of Fampridine Accord is important to maintain the stability and effectiveness of the medication, particularly the integrity of the prolonged-release coating, which is essential for safe dosing. The medication should be stored at a temperature not exceeding 25°C (77°F). Avoid exposure to excessive heat or direct sunlight, as temperature extremes can compromise the prolonged-release properties of the tablet formulation.

Keep the tablets in the original blister packaging until immediately before use. The blister packaging provides protection from moisture and light, both of which can affect the stability of fampridine. Do not transfer the tablets to another container, such as a weekly pill organizer, unless they will be used within a short time frame (a few days at most), as prolonged exposure to ambient humidity and light may degrade the formulation.

Always check the expiry date printed on the blister pack and outer carton before taking a tablet. Do not use Fampridine Accord after the expiry date. Expired medication may not provide the intended therapeutic effect and could potentially have altered release characteristics, affecting safety. Keep all medications out of the sight and reach of children. Do not dispose of medications in household waste or via wastewater. Return unused or expired tablets to your pharmacy for proper disposal in accordance with local regulations.

What Does Fampridine Accord Contain?

The active substance in Fampridine Accord is fampridine (also known chemically as 4-aminopyridine). Each prolonged-release tablet contains exactly 10 mg of fampridine. The chemical formula of fampridine is C₅H₆N₂, with a molecular weight of 94.11 g/mol. It is a small, water-soluble molecule that is rapidly and completely absorbed from the gastrointestinal tract.

The excipients (inactive ingredients) in the tablet core include hypromellose (hydroxypropyl methylcellulose), which serves as the primary matrix-forming polymer responsible for the prolonged-release characteristics of the tablet. When the tablet comes into contact with gastrointestinal fluids, hypromellose swells to form a gel layer that controls the rate at which fampridine is released. Other tablet core excipients include microcrystalline cellulose (a filler and binding agent), colloidal anhydrous silica (a flow agent), and magnesium stearate (a lubricant used during tablet manufacturing).

The film coating of the tablet contains hypromellose, titanium dioxide (E171, a white colorant), and macrogol (polyethylene glycol, which provides a smooth coating). The film coat protects the tablet from moisture and makes it easier to swallow. The resulting tablet is white to off-white, biconvex, and oval-shaped.

It is important to note that the prolonged-release formulation is a critical aspect of the medication’s safety profile. The matrix-controlled release system is designed to provide a gradual, sustained release of fampridine over several hours, producing lower and more stable plasma concentrations compared to immediate-release formulations. This controlled release significantly reduces the risk of concentration-dependent seizures. Any alteration to the tablet (crushing, breaking, chewing) destroys this mechanism and can lead to potentially dangerous rapid release of the entire dose.

References

1. European Medicines Agency (EMA). Fampyra (fampridine) — Summary of Product Characteristics. Last updated 2024. Available from: EMA — Fampyra.
2. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373(9665):732-738. doi:10.1016/S0140-6736(09)60442-6.
3. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68(4):494-502. doi:10.1002/ana.22240.
4. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777-788. doi:10.1212/WNL.0000000000005347.
5. National Institute for Health and Care Excellence (NICE). Fampridine for treating walking disability in people with multiple sclerosis. Technology Appraisal Guidance [TA832]. 2022.
6. Dunn J, Blight A. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin. 2011;27(7):1415-1423. doi:10.1185/03007995.2011.583229.
7. U.S. Food and Drug Administration (FDA). Ampyra (dalfampridine) Extended Release Tablets — Prescribing Information. Revised 2023.
8. Hobart J, Blight AR, Goodman A, et al. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 2013;80(16):1509-1517. doi:10.1212/WNL.0b013e31828cf7f3.
9. World Health Organization (WHO). Model List of Essential Medicines — 23rd List, 2023. Geneva: WHO; 2023.

About Our Medical Editorial Team

This article was written and reviewed by the iMedic Medical Editorial Team, which includes board-certified neurologists and clinical pharmacologists with expertise in multiple sclerosis treatment, neuropharmacology, and drug safety. Our editorial process follows the GRADE evidence framework, and all medical claims are supported by peer-reviewed evidence from established international sources including the EMA, FDA, NICE, and the American Academy of Neurology (AAN).